Table 2.
Antibody | Isotype control |
---|---|
FITC‐conjugated anti‐CD3 (BD Biosciences, San Diego, CA) | FITC‐mouse IgG1 κ (BD Biosciences, San Diego, CA) |
PE‐Cy7‐conjugated anti‐CD4 (BioLegend, San Diego, CA) | PE‐Cy7‐Rat IgG 2b κ (BioLegend, San Diego, CA) |
PE‐Cy5‐conjugated anti‐CD8 (BD Biosciences, San Diego, CA) | FITC‐mouse IgG1 κ (BD Biosciences, San Diego, CA) |
PE‐Cy5‐conjugated anti‐CD19 (BD Biosciences, San Diego, CA) | PECy5‐mouse IgG1 κ (BD Biosciences, San Diego, CA) |
PE‐conjugated anti‐HLA‐DR (BD Biosciences, San Diego, CA) | PE‐mouse IgG2a κ (BD Biosciences, San Diego, CA) |
BV510‐conjugated anti‐CD69 (BioLegend, San Diego, CA) | BV510‐mouse IgG1 κ (BioLegend, San Diego, CA) |
Abbreviations: BV510, brilliant violet 510; Cy5, cyanine 5; FITC, fluorescein isothiocyanate; PE, phycoerythrin.
All antibodies were validated and titrated using biological and/or isotype control.